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Abstract 39 
 40 
Objective: Experimental evidence suggests that aldosterone directly contributes to organ damage 41 
by promoting cell growth, fibrosis, and inflammation. Based on these premises, this work aimed to 42 
assess the glomerular effects of aldosterone, alone and in combination with salt. 43 
Methods: After undergoing uninephrectomy, seventy-five rats were allocated to five groups: 44 
control, salt diet, aldosterone, aldosterone + salt diet, aldosterone + salt diet and eplerenone, and 45 
they were all studied for four weeks. We focussed on glomerular structural, functional, and 46 
molecular changes, including slit diaphragm components, local renin-angiotensin system (RAS) 47 
activation as well as pro-oxidative and profibrotic changes.  48 
Results: Aldosterone significantly increased systolic blood pressure, led to glomerular hypertrophy, 49 
mesangial expansion, and it significantly increased the glomerular permeability to albumin and the 50 
albumin excretion rate, indicating the presence of glomerular damage. These effects were worsened 51 
by adding salt to aldosterone, while they were reduced by eplerenone. Aldosterone-induced 52 
glomerular damage was associated with glomerular angiotensin-converying enzyme (ACE) 2 53 
downregulation, with ACE/ACE2 ratio increase, ANP decrease, as well as with glomerular pro-54 
oxidative and profibrotic changes.  55 
Conclusions: Aldosterone damages not only the structure but also the function of the glomerulus. 56 
ACE/ACE2 upregulation, ACE2 and ANP downregulation, pro-oxidative and profibrotic changes 57 
are possible mechanisms accounting for aldosterone-induced glomerular injury 58 
59 
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INTRODUCTION 60 
 61 
Aldosterone is a mineralocorticoid hormone, whose effects are mediated by the binding to 62 
the mineralocorticoid receptors (MR), which are located in both epithelial and non-epithelial 63 
tissues [1,2]. In the kidney, aldosterone acts not only on distal tubule epithelial cells, where it leads 64 
to sodium reabsorption and potassium excretion, but also on mesangial cells, podocytes, 65 
fibroblasts, and on glomerular vascular cells [3]. In recent years there has been a paradigm shift in 66 
our understanding of aldosterone actions [3], which go far beyond sodium and potassium transport 67 
in the renal tubule and involve the ability of this hormone to modulate the local renin-angiotensin 68 
system (RAS) [4,5], generate reactive oxygen species [6], and promote fibrosis [7].  69 
It has been shown that there is a correlation between kidney damage and circulating 70 
aldosterone [8,9,10], which could be due to aldosterone pro-oxidative, pro-inflammatory, and pro-71 
fibrotic effects, overall leading to glomerulosclerosis and tubulo-interstitial fibrosis [3]. This is 72 
consistent with experimental studies showing that MR antagonists, such as spironolactone and 73 
eplerenone, protect against progressive renal injury [11,12,13].  74 
Although it is abundantly clear that aldosterone causes renal damage, it has not been fully 75 
elucidated yet how this hormone affects the glomerulus and whether it could damage the 76 
glomerular filtration barrier. Based on these observations, here we studied: (i) to what extent the 77 
glomerular permeability to albumin is affected by aldosterone; (ii) what are aldosterone molecular 78 
targets in isolated glomeruli (focusing on slit diaphragm components, local RAS mediators, pro-79 
oxidative and profibrotic molecules), and (iii) whether aldosterone-induced changes are due to the 80 
binding to MR receptors.  81 
82 
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 83 
MATERIALS AND METHODS 84 
 85 
Animal model and experimental protocol 86 
To evaluate aldosterone effects, the animal model that we chose was that of uninephrectomized, 87 
high-salt diet fed rats infused with aldosterone [8]. This is a well-established animal model to study 88 
aldosterone effects [8], where both uninephrectomy and salt accelerate aldosterone-induced kidney 89 
damage. Several works have in fact demonstrated that salt and aldosterone synergistically 90 
contribute to renal impairment [14-16]. Moreover, to discriminate the contribution of salt to 91 
glomerulosclerosis development, we randomized the rats to either salt or aldosterone, or both. 92 
Based on these premises, 75 wild-type male Wistar rats, weighing 250 g, underwent left 93 
uninephrectomy at baseline and were randomized to 5 different groups one week after. A total of 94 
15 rats were fed with a 0.2% NaCl diet, considered the control diet (CNT), 15 rats were fed with a 95 
1.2% NaCl diet, considered the high-salt diet (SALT), 15 rats were fed with a 0.2% NaCl diet and 96 
treated with aldosterone at a dose of 72 µg/Kg/day (ALDO), 15 rats were fed with a 1.2% NaCl 97 
diet and treated with aldosterone (ALDO+SALT) and 15 rats were fed with a 1.2% NaCl diet and 98 
treated with aldosterone and its antagonist eplerenone at a dose of 100 mg/Kg/day (EPL). All the 99 
rats were fed with the Harlan Teklad 18% Protein Global Diet (Harlan Laboratories, Cat#2018), 100 
which contains 0.2% NaCl, 44.2% of carbohydrates, 18.6% of proteins, 18.2% of fibers, and 6.2% 101 
of fat. The rats of the SALT and ALDO+SALT groups had also the 1.2% NaCl solution to drink. 102 
Aldosterone was infused using an Alzet 2004-osmotic minipump (Alzet 2ML4model; AzaCorp, 103 
Palo Alto, California, USA) and its dose was chosen taking into account what has been published 104 
previously [8]. Eplerenone (Sigma, Cat#E6657) was administered incorporated into the Harlan 105 
Teklad 18% rodent diet at a concentration of 1.2 mg/g of chow (∼100 mg/kg/day). Previous works 106 
have demonstrated the stability and efficacy of this dose of eplerenone incorporated into the diet 107 
[8,14]. All the rats were then followed for 4 weeks. At the end of the study, systolic blood pressure 108 
(SBP) was assessed by tail cuff plethysmography, and the rats were then placed in individual 109 
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metabolic cages for 24 hours so that water intake could be recorded and total urine output 110 
collected. After performing these procedures the animals were sacrificed, and bloods and kidneys 111 
were collected for biochemical, morphological, and molecular analyses. The rats were housed at 112 
the animal house of Trieste University and were studied according to Institutional guidelines. 113 
This study was carried out in strict accordance with the recommendations in the Guide for the Care 114 
and Use of Laboratory Animals of the National Institutes of Health. A committee of the Italian 115 
Health Ministry approved the experimental protocol (Permit Number: prot 85 pos II/9 10/02/2006). 116 
The animals were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol (Sigma 117 
Chemical, St Louis, MO, USA), at a dose of 25mg/100g of body weight. Buprenorfine (Temgesic, 118 
Reckitt, Benckiser) was used as analgesic and was injected subcutaneously at a dose of 0.05 mg/Kg 119 
the day of the intervention and at a dose of 0.025 mg/Kg the day after. All  efforts were made to 120 
minimize suffering. 121 
 122 
General parameters and biochemical data 123 
Body weight, relative kidney mass (kidney weight/body weight), SBP, daily water intake, daily 124 
urinary volume, daily sodium excretion, AER (albumin excretion rate), serum potassium, 125 
creatinine, and aldosterone were measured at the end of the study in all the rats. Urinary sodium, 126 
serum potassium, and creatinine were assessed by autoanalyzer. Urinary AER was measured by 127 
ELISA (Bethyl Laboratories, IMTEC Diagnostics, Antwerpen, Belgium). Serum aldosterone was 128 
determined by EIA (DRG diagnostics international, Marburg, Germany). Urinary nephrin was 129 
measured by ELISA (Exocell, Philadelphia, USA). 130 
 131 
Assessment of glomerular albumin permeability 132 
A total of 18-20 glomeruli were isolated from half kidney by standard sieving technique in media 133 
containing 50 g/L of bovine serum albumin (BSA) in PBS as an oncotic agent. Half of them were 134 
used for albumin permeability (Palb) assessment and half for RNA extraction. The glomeruli that 135 
were used for Palb assessment were incubated for 10 min at 37°C and then transferred to a glass 136 
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coverslip where they were videotaped after a passage from a media containing 50g/L of BSA to a 137 
media containing 10g/L of BSA. This media change creates an oncotic gradient across the 138 
basement membrane, resulting in a glomerular volume change [∆V = (Vfinal – V initial)/Vinitial], which 139 
we measured off-line by a video-based image analysis program. In particular, since the computer 140 
program allows to determine the average glomerular radius in a two-dimensional space, the 141 
glomerual volume can be calculated by the formula V=4/3πr
3
. Then σalb, which expresses the 142 
degree of membrane permeability or leakiness, can be calculated by the formula 143 
(σalb)=(∆V)experimental/(∆V)control, and Palb, which refers to the movement of albumin subsequent to 144 
water flux, can be calculated by the formula 1- σalb [17]. 145 
 146 
Kidney structural features 147 
Two coronal 3-µm paraffin kidney sections were stained with hematoxylin-eosine, for tubular and 148 
glomerular area measurement, as described previously [18], and with periodic acid-Schiff, for 149 
mesangial matrix score assessment. The amount of mesangial matrix was scored with a range from 150 
0 to 4 (0 is for no changes; 1 is for changes affecting < 25%; 2 is for changes affecting 25-50%; 3 151 
is for changes affecting 50-75%; 4 is for changes affecting > 75% of the glomerulus). For further 152 
details see supplementary data. 153 
 154 
Gene expression quantification by qRT-PCR  155 
A total of 3 µg of RNA extracted from isolated glomeruli were used to synthesize cDNA with 156 
Superscript First Strand synthesis system for qRT-PCR (Gibco BRL, Grand Island, NY, USA), as 157 
previously described [19,20]. Gene expression was analysed by real-time qRT-PCR using the 158 
TaqMan system based on real-time detection of accumulated fluorescence (ABI Prism 7900 HT, 159 
Perkin-Elmer Inc, Foster City, CA, USA). In order to control for variation in the amount of cDNA 160 
available in the samples, gene expression of the target sequence was normalized in relation to the 161 
expression of an endogenous control, 18s ribosomal RNA, and then reported as arbitrary units 162 
compared to the level of expression in untreated control, which were given an arbitrary value of 1. 163 
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In particular, we analysed the glomerular gene expression of ACE (angiotensin-converting 164 
enzyme), ACE2 (angiotensin-converting enzyme 2), ANP (atrial natriuretic peptide), CD2AP 165 
(CD2-adaptor protein), CTGF (connective tissue growth factor), CuZnSOD (copper zinc 166 
superoxide dismutase), iNOS (inducible nitric oxide synthase), MMP-9 (matrix metallopeptidase-167 
9), MnSOD (manganese superoxide dismutase), nephrin, NOX4 (NADPH oxidase 4), podocin, and 168 
USP2 (ubiquitin-specific protease 2).  For probe and primers sequences see Supplementary Table 169 
1. 170 
 171 
Immunostainings 172 
Glomerular ACE, ACE2, ANP (atrial natriuretic peptide), CTGF, and nitrotyrosilated proteins were 173 
quantified by immunostainings on 4-µm paraffin kidney sections. Kidney sections were incubated 174 
with the following primary antibodies: mouse anti-ACE (Chemicon, Temecula, CA, USA, diluition 175 
1:100); goat anti-ACE2 (R&D Systems, Minneapolis, MN, USA, diluition 1:100); rabbit anti-ANP 176 
(Millipore, Billerica, MA, USA, diluition 1:200), rabbit anti-CTGF (Abcam, Cambridge, UK, 177 
dilution 1:200), rabbit anti-nitrotyrosine (Upstate, Lake Placid, NY, USA, diluition 1:100). For 178 
more details on these primary antibodies see Supplementary Table 2. Biotinylated 179 
immunoglobulins (Vector Laboratories, Burlingame, CA, USA), were diluted 1:500 for ACE and 180 
ACE2, and 1:200 for ANP, CTGF, and nitrotyrosine and applied as secondary antibodies. Sections 181 
were counterstained with either Aniline blue (Ventana, France) or hematoxylin. A total of three 182 
sections per animal were analyzed, where a minimum of 20 glomeruli per section were counted. 183 
The percentage area occupied by the stainings was calculated within the glomeruli. The results 184 
were expressed as the percentage of positive staining per glomerulus, that is percentage stained 185 
area.  186 
 187 
Statistical analysis  188 
The data were evaluated by analysis of variance (ANOVA) calculated using Statview 512 software 189 
for Apple Macintosh computer (Brainpower, Calabasas, California, USA). Mean comparisons were 190 
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performed by Fisher least significant difference method (post-hoc test). Linear regression analysis 191 
was used for testing two variable relationships. Results were expressed as mean ± SEM, unless 192 
otherwise specified. The criterion for statistical significance was p<0.05. 193 
194 
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 195 
RESULTS 196 
 197 
General parameters and biochemical data  198 
Salt led to a significant increase in water intake, urinary volume, and sodium urinary excretion over 199 
24 hours compared to the controls (Table 1). Aldosterone infusion significantly raised blood 200 
pressure levels and reduced serum potassium. Hypertension and hypokalemia were even greater 201 
when aldosterone was administered in combination with the salt diet and were significantly 202 
reduced by eplerenone, as shown in Table 1. In our study, aldosterone levels increased by 3.6 203 
times in the rats infused with it, mimicking what is seen in patients with idiopathic 204 
hyperaldosteronism or aldosterone-producing adenomas where aldosterone levels increase by 2.67-205 
3.82 times as compared to patients with essential hypertension [21]. 206 
 207 
Renal structural features 208 
Both salt and aldosterone led to kidney and tubular hypertrophy, as compared to the controls 209 
(Table 2). These effects were accentuated by combining salt to aldosterone, whereas they were 210 
blunted by eplerenone. Only aldosterone infusion, though, led to glomerular hyperthropy, which 211 
was significantly more pronounced in the high-salt diet fed rats, whilst it was reduced by 212 
eplerenone (Table 2). Consistent with these changes, aldosterone infusion only led to glomerular 213 
hypercellularity and to mesangial expansion, which corresponds to the dark pink staining that can 214 
be seen in Fig. 1 and whose score is reported in Table 2. These changes were more pronounced in 215 
the high-salt diet fed rats, where they were partially reduced by eplerenone.  216 
 217 
Aldosterone and the glomerular filtration barrier 218 
Aldosterone-induced glomerular structural changes (hypertrophy and mesangial expansion) were 219 
associated with a significant increase in glomerular Palb and AER (Table 2). In particular, there was 220 
a significant correlation between glomerular Palb and both glomerular hypertrophy (r=0.550; 221 
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p<0.001) and AER (r=0.516; p<0.01). Having said that, we did not find any change in the 222 
glomerular gene expression of nephrin, podocin, CD2AP, and USP2 between the groups studied 223 
(data not shown). Moreover, urinary nephrin was almost undetectable in the groups studied (data 224 
not shown).  225 
  226 
Glomerular renin-angiotensin system  227 
The gene expression of ACE, ACE2, and ANP was measured in the glomeruli of all the groups of 228 
rats, where we found that salt and aldosterone significantly upregulated ACE and downregulated 229 
ACE2 gene and protein expression (Fig. 2). Similarly to ACE2, also ANP was significantly 230 
downregulated by aldosterone (Fig. 2). All these changes were abolished by eplerenone (Fig. 2).  231 
 232 
Glomerular pro-oxidative and profibrotic changes 233 
Since the generation of oxidative stress and the balance between production and degradation of 234 
extracellular matrix play an important role in aldosterone-driven kidney damage [3], we decided to 235 
evaluate the glomerular expression of molecules involved in these processes. In particular, we 236 
focussed on CuZnSOD, iNOS, MnSOD, and NOX4 as well as on CTGF and MMP-9, whose gene 237 
expression was measured in the glomeruli previously isolated from the kidneys of all the groups of 238 
rats. With respect to oxidative stress generation, although the glomerular expression of MnSOD 239 
and NOX4 did not change between the groups studied (data not shown), CuZnSOD, which is an 240 
anti-oxidant, and iNOS, which is a pro-oxidant, were significantly down- and upregulated, 241 
respectively, in the glomeruli of the ALDO+SALT rats (Fig. 3). The staining for nitrosylated 242 
proteins, which are a marker of oxidative stress, showed that there was a significant increase in 243 
glomerular nitrotyrosine in the SALT, ALDO, and ALDO+SALT groups, and that eplerenone 244 
reduced it significantly (Fig. 3).  245 
In terms of profibrotic changes, aldosterone combined with salt significantly upregulated CTGF 246 
and downregulated MMP-9 glomerular gene expression (Fig. 4). This was consistent with CTGF 247 
immunostaining showing a significant increase of this protein expression in the glomeruli of the 248 
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rats treated with aldosterone alone or in combination with salt (Fig. 4). Eplerenone significantly 249 
reduced these effects (Fig. 4). 250 
 251 
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 252 
DISCUSSION 253 
 254 
This work aimed at investigating the glomerular effects of aldosterone, alone and in 255 
combination with salt, and we found that aldosterone damages the glomerulus, where it induces 256 
structural and functional changes. In particular, this is the first study where the glomerular 257 
permeability to albumin has been measured in aldosterone-infused rats. Here we found that 258 
aldosterone significantly increased the glomerular permeability to albumin and albuminuria, which 259 
were positively correlated, in line with the concept that albuminuria is related to an alteration of 260 
glomerular permeability. To test the hypothesis that aldosterone increases glomerular permeability 261 
by damaging the slit diaphragm [22-23] we studied three important proteins of the slit diaphragm, 262 
which are nephrin, podocin, and CD2AP, whose mutations have been linked to nephrotic syndrome 263 
development [24]. In addition, we also quantified USP2, which seems to play a role in mesangial 264 
cell proliferation during glomerulonephritis [25]. Contrary to what has been previously reported 265 
[22], we found no changes in the glomerular expression of these genes. Likewise, urinary nephrin 266 
was almost undetectable, suggesting that there was no podocyte loss. A first explanation to this 267 
negative data may be ascribed to the percentage of salt of our diet as compared to the 8% salt diet 268 
used by Shibata et al. [22], given that the 8% salt diet usually worsens glomerular damage as 269 
compared to the 1.2% salt diet [18]. Secondly, it is also possible that aldosterone needs a much 270 
longer period of time before it damages the podocytes [26], consistent with the observation that the 271 
downregulation of slit diaphragm proteins correlates with the stage of glomerular damage [27]. In 272 
the third place, proteinuria does not only rely on podocyte changes [28] [29] but it can also be 273 
ascribed to abnormalities of endothelium and basement membrane [30].  274 
 275 
 Consistent with the concept that a high-salt diet has a detrimental effect on kidney function 276 
[18], and that it worsens the glomerular changes due to aldosterone [15], here we found that the 277 
ALDO+SALT group displayed the highest degree of glomerular permeability to albumin and 278 
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proteinuria. The fact that salt worsens the effect of aldosterone is due to the ability of salt to cause 279 
paradoxical MR activation through Rac1 [31], which modulates MR activity, as the inhibition of 280 
the Rac-1-MR cascade by eplerenone ameliorates salt-mediated kidney injury [16]. Here we found 281 
that eplerenone reduced most, but not all, aldosterone-driven effects. This suggests that other 282 
mechanisms than MR activation are involved in the aldosterone/salt-induced nephropathy, such as 283 
the non-genomic effects that aldosterone can exerts in the absence of MR activation [32]. 284 
Moreover, for other authors [33] the reason underlying the discrepancy between the degree of 285 
aldosterone-induced renal damage and the modest effect of eplerenone is that aldosterone levels 286 
may be too high to be efficiently counteracted by MR antagonists.   287 
  288 
 In recent years there has been a paradigm shift in our understanding of aldosterone actions, 289 
which go far beyond sodium and potassium transport in the renal tubule and involve the ability of 290 
this hormone to stimulate the local renin-angiotensin system (RAS) [4,5], generate reactive oxygen 291 
species [6], and promote fibrosis [7], whereby it leads to organ damage [7]. It is well known that 292 
the activation of the RAS is involved in the development and progression of kidney disease, as its 293 
blockade is one of the most efficient ways to reduce proteinuria as well as to delay renal 294 
insufficiency [3]. Such blockade has traditionally focussed on inhibiting the synthesis of 295 
Angiotensin (Ang) II, and/or preventing activation of Ang II type 1 receptor. Nevertheless, the 296 
degradation of Ang II is also important [34] and the major enzyme that converts Ang II to Ang 1-7 297 
is ACE2 [35]. So, it is the balance between ACE and ACE2 that is currently considered critical for 298 
the activation of renal RAS [36,37]. Having said that, the second novel aspect of this work is that 299 
we show the effect that aldosterone, alone and in combination with salt, has on ACE2 glomerular 300 
expression in vivo. Here salt and aldosterone significantly reduced ACE2 expression, while ACE 301 
increased, leading to an upregulation of ACE/ACE2 ratio, which is in line with previous 302 
observations [38,39]. Now, based on recent experimental evidence [40,41,42], it is possible to 303 
speculate that the glomerular changes that follow aldosterone infusion are partly relying on ACE2 304 
downregulation. First of all, ACE2 deficiency/inhibition alone can increase glomerular ACE gene 305 
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and protein expression [18][43], with a subsequent increase of local Ang II. Secondly, ACE2 306 
downregulation contributes to aldosterone-induced glomerular changes, as ACE2 deficiency has 307 
been found associated with pro-oxidative, proinflammatory, and profibrotic glomerular changes 308 
[40,41,42]. It should be noted that ACE2 protects the kidney not only by Ang II degradation, but 309 
also by Ang 1-7 and ANP generation [40], which are both renoprotective [44][45][46]. In line with 310 
the concept that ACE2 regulates ANP renal production [40], here we found that aldosterone 311 
significantly reduced also ANP glomerular expression, which is the third novel aspect of this paper.  312 
 313 
Besides RAS activation, which interacts with aldosterone in inducing tissue damage, 314 
aldosterone led to pro-oxidative and profibrotic changes, which were reduced by eplerenone, and 315 
can also underpin the glomerular changes that we observed. On one hand, ROS production might 316 
have in fact contributed to the glomerular functional changes induces by aldosterone, as superoxide 317 
and hydroxyl radicals increase the glomerular permeability to albumin (possibly by lipid 318 
peroxidation of cell membrane cytoskeleton), and this is reversed by blocking these mediators with 319 
scavengers [47]. On the other hand, also CTGF upregulation could explain glomerular structural 320 
and functional changes. CTGF, which is not normally expressed in the healthy kidney, is induced 321 
in the early stages of renal diseases [48] and its levels correlate with the severity and progression of 322 
renal fibrosis [49]. Interestingly, it has been shown that CTGF induces mesangial cell cycle arrest, 323 
mesangial cell hypertrophy, and mesangial matrix expansion in renal non-epithelial cells [50], as 324 
well as that CTGF can damage the slit diaphragm [51]. Moreover, treatment of diabetic mice with 325 
CTGF antisense oligonucleotide attenuates albuminuria [52].  326 
 327 
In conclusion, our work further characterizes the effects of aldosterone on the glomerulus. 328 
Here we show that aldosterone infusion induces glomerular hypertrophy, mesangial expansion, and 329 
it increases the glomerular permeability to albumin. These aldosterone-induced glomerular effects 330 
are likely to be mediated by the binding to the mineralocorticoid receptors, as eplerenone reverses 331 
them. In particular, we speculate that some of the aldosterone effects might depend on RAS 332 
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activation, as aldosterone significantly reduced ACE2, increased the ACE/ACE2 ratio, and 333 
decreased ANP, which were partly reversed by eplerenone. Besides RAS activation, aldosterone 334 
led also to local oxidative stress generation and profibrotic changes, which altogether might have 335 
contributed to the induction of glomerular damage. 336 
337 
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TABLE HEADINGS 449 
 450 
Table 1. General parameters and biochemical data. Data are expressed as mean ± SEM; * 451 
p<0.05 vs CNT; † p<0.05 vs ALDO; ‡ p<0.05 vs ALDO+SALT. ALDO is aldosterone and 0.2% 452 
NaCl diet; ALDO+SALT is aldosterone and 1.2% NaCl diet; BW is body weight; CNT is 0.2% 453 
NaCl diet; EPL is aldosterone, eplerenone and 1.2% NaCl diet; SALT is 1.2% NaCl diet; SBP is  454 
systolic blood pressure 455 
 456 
Table 2. Glomerular structural and functional features. Data are expressed as mean ± SEM; * 457 
p<0.05 vs CNT; † p<0.05 vs ALDO; ‡ p<0.05 vs ALDO+SALT. AER is albumin excretion rate; 458 
ALDO is aldosterone and 0.2% NaCl diet;  ALDO+SALT is aldosterone and 1.2% NaCl diet; CNT 459 
is 0.2% NaCl diet; EPL is aldosterone, eplerenone and 1.2% NaCl diet; Palb is albumin 460 
permeability; SALT is 1.2% NaCl diet.  461 
462 
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LEGENDS TO FIGURES 463 
 464 
Figure 1. Effect of aldosterone, alone or in combination with salt, on mesangial matrix 465 
expansion. Representative PAS stained sections of kidneys (original magnification 25X). (A) 466 
CNT; (B) SALT; (C) ALDO; (D) ALDO+SALT; (E) EPL. ALDO is aldosterone and 0.2% NaCl 467 
diet; ALDO+SALT is aldosterone and 1.2% NaCl diet; CNT is 0.2% NaCl diet; EPL is 468 
aldosterone, 1.2% NaCl diet, and eplerenone; SALT is 1.2% NaCl diet. 469 
Figure 2. Effect of aldosterone, alone or in combination with salt, on glomerular RAS. (A) 470 
Glomerular ACE, ACE2, and ANP messenger RNA expression, reported as relative gene units. 471 
Data are expressed as mean ± SEM. * p < 0.05 vs CNT; ‡ p < 0.05 vs ALDO+SALT. (B) 472 
Glomerular ACE, ACE2, and ANP protein expression, reported as percentage stained area. Data 473 
are expressed as mean ± SEM. * p < 0.05 vs CNT; † p < 0.05 vs ALDO; ‡ p < 0.05 vs 474 
ALDO+SALT. (C-Q) Representative ACE (upper panel), ACE2 (middle panel), and ANP (lower 475 
panel) immunostained sections of glomeruli (original magnification 25X). (C, H, M) CNT; (D, I, 476 
N) SALT; (E, J, O) ALDO; (F, K, P) ALDO+SALT; (G, L, Q) EPL.   477 
ACE is angiotensin-converting enzyme; ACE2 is angiotensin-converting enzyme 2; ALDO, is 478 
aldosterone and 0.2% NaCl diet; ALDO+SALT is aldosterone and 1.2% NaCl diet; ANP is atrial 479 
natriuretic peptide; CNT is 0.2% NaCl diet; EPL is aldosterone, 1.2% NaCl diet, and eplerenone; 480 
RAS is renin-angiotensin system; SALT is  1.2% NaCl diet. 481 
Figure 3. Effect of aldosterone, alone or in combination with salt, on glomerular oxidative 482 
stress. (A) Glomerular CuZnSOD and iNOS messenger RNA expression, reported as relative gene 483 
units. Data are expressed as mean ± SEM. * p < 0.05 vs CNT; ‡ p < 0.05 vs ALDO+SALT. (B) 484 
Glomerular nitrotyrosine protein expression, reported as percentage stained area. Data are 485 
expressed as mean ± SEM. * p < 0.05 vs CNT; # p < 0.05 vs SALT; † p < 0.05 vs ALDO; ‡ p < 486 
0.05 vs ALDO+SALT. (C-G) Representative nitrotyrosine immunostained sections of glomeruli 487 
(original magnification 25X). (C) CNT; (D) SALT; (E) ALDO; (F) ALDO+SALT; (G) EPL. 488 
ALDO is aldosterone and 0.2% NaCl diet; ALDO+SALT is aldosterone and 1.2% NaCl diet; CNT 489 
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is 0.2% NaCl diet; CuZnSOD is copper zinc superoxide dismutase; EPL is aldosterone, 1.2% NaCl 490 
diet, and eplerenone; iNOS is inducible nitric oxide synthase; SALT is 1.2% NaCl diet. 491 
Figure 4. Effect of aldosterone, alone or in combination with salt, on glomerular profibrotic 492 
changes. (A) Glomerular CTGF and MMP-9 messenger RNA expression, reported as relative gene 493 
units. Data are expressed as mean ± SEM. * p < 0.05 vs CNT; ‡ p < 0.05 vs ALDO+SALT. (B) 494 
Glomerular CTGF protein expression, reported as percentage stained area.  Data are expressed as 495 
mean ± SEM. * p < 0.05 vs CNT; ‡ p < 0.05 vs ALDO+SALT. (C-G) Representative CTGF 496 
immunostained sections of glomeruli (original magnification 25X). (C) CNT; (D) SALT; (E) 497 
ALDO; (F) ALDO+SALT; (G) EPL. ALDO is aldosterone and 0.2% NaCl diet; ALDO+SALT is 498 
aldosterone and 1.2% NaCl diet; CNT is 0.2% NaCl diet; CTGF is connective tissue growth factor; 499 
EPL is aldosterone, 1.2% NaCl diet, and eplerenone; MMP-9 is matrix metallopeptidase-9; SALT 500 
is 1.2% NaCl diet. 501 
 502 
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Table 1.  
  
CNT 
 
SALT 
 
ALDO 
 
ALDO+SALT 
 
EPL 
BW (g) 326.6±5.7 319.7±11.3 326.0±4.2 321.4±5.7 321.2±6.9 
 
SBP (mmHg) 117.8±1.6 116.6±2.0 154.7±1.6* 168.8±2.1*† 133.3±2.4*‡ 
 
Water intake  
(ml/100g BW) 
6.8±0.8 16.5±1.1* 8.6±0.8 18.5±1.7* 13.9±1.2* 
Urinary volume  
(ml/100g BW) 
10.1±0.3 31.0±2.7* 13.7±1.3 42.1±5.1* 32.0±3.1* 
Urinary sodium  
(mEq/100g BW/day) 
0.4±0.1 3.0±0.2* 0.5±0.1 3.5±0.4* 3.4±0.3* 
Serum potassium 
(mEq/l)  
6.1±0.2 6.5±0.2 3.9±0.2* 3.3±0.1*† 4.6±0.2*‡ 
Serum aldosterone  
(pg/ml) 
249±27 213±32 988±117* 978±100* 805±74* 
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Table 2.  
  
CNT 
 
SALT 
 
ALDO 
 
ALDO+SALT 
 
EPL 
 
Kidney structural features 
Renal mass  
(mg KW/ g BW) 
3.85±0.09 4.13±0.05* 4.51±0.06* 5.63±0.09*† 4.66±0.09*‡ 
Tubular area  
(µm
2
) 
1403±19.9 1473±25.8* 1479±22.1* 1738±26.2*† 1380±17.8*‡ 
Glomerular  
area (µm
2
) 
8112±77 8209±84 8852±101* 9633±136*† 9201±98*‡ 
Mesangial 
matrix score 
0.5 ± 0.01 0.5 ± 0.01 2.5 ± 0.02* 3.0 ± 0.04*† 2.2 ± 0.15*‡ 
 
Glomerular functional features 
Palb 
(arbitrary units) 
0.08±0.03 
 
0.11±0.07 0.34±0.08 0.53±0.05* 0.27±0.06*‡ 
AER  
(mg/24h) 
0.62±0.07 0.55±0.1 0.80±0.06 3.19±0.41* 2.03±0.69*‡ 
Creatinine  
(mg/dl) 
0.44±0.02 0.42±0.01 0.38±0.02 0.38±0.02 0.38±0.01 
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Supplementary table 1.  
 
Gene of interest 
 
 
 
Sequences 
ACE Probe  
F primer 
R primer 
6- FAM CCACCTGCTGGTCC 
TACAACTCTCTGCTAAGCAACATGAG 
CTTGGCATAGTTTCGTGAGGAA 
ACE2 Probe 
F primer 
R primer 
6- FAM TTGTCTGCCACCCCACA 
GCCAGGAGATGACCGGAAA 
CTGAAGTCTCCATGTCCCAGATC 
ANP 
 
Probe 
F primer 
R primer 
6- FAM CCAGGCCATATTGGA 
CTTCCTCTTCCTGGCCTTTTG 
CGCACTGTATACGGGATTTGC 
CD2AP 
 
Probe 
F primer 
R primer 
6- FAM ACGCTCAGGAGGAAT 
CACAGAGGATGGTGAAATGCA 
GGTAGGGCCAGACAAAGAAACTT 
CTGF 
 
Probe 
F primer 
R primer 
6- FAM ACTGCCTGGTCCAGAC 
TGGCCCTGACCCAACTATGA 
CTTAGAACAGGCGCTCCACTCT 
CuZnSOD 
  
Probe 
F primer 
R primer 
6- FAM TGTGATCTCACTCTCAGGAG 
GGACGGTGTGGCCAATGT 
CGGCCAATGATGGAATGC 
iNOS 
 
Probe 
F primer 
R primer 
6-FAM CTTCCGCATTAGCACAGAA 
TGGTGAAAGCGGTGTTCTTTG 
ACGCGGGAAGCCATGA 
MMP-9 
 
Probe 
F primer 
R primer 
6- FAM CATCAAAAACATCCACATTG 
TCTTCGACTCCAGTAGACAATCCTT 
GCCCTGGATATCAGCAATGG 
MnSOD Probe 
F primer 
R primer 
6- FAM CCTGAGCCCTAAGGG 
GCCTGCACTGAAGTTCAATGG 
ATAGCCTCCAGCAACTCTCCTTT 
Nephrin Probe 
F primer 
R primer 
6- FAM AGCATGCCCAGGCAG 
AGTGGCTGAAGAACGGTAAACC 
TGAGCCGAGCTCCATGGT 
NOX4 Probe 
F primer 
R primer 
6- FAM CATTTTGCTATTTCATCAAA 
CGTCCTCGGTGGAAGCTTT 
AAACTCCAACTGTTTTCCCTCTGT 
Podocin Probe 
F primer 
R primer 
6- FAM CCCGCACTTTGGCCT 
TGGAAGCTGAGGCACAAAGA 
CCCCTTCGGCAGCAATC 
USP2 F primer 
R primer 
CAGACCCGTGGCAATGAAA 
GCTGTTCGATTTCTTCTGGC 
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Supplementary Table 2.  
Antigen 
name 
 Clonality 
Host 
species 
Supplier 
Catalogue  
number 
Antigen(s) used to raise the 
antibody 
Final 
dilution 
 
References 
ACE monoclonal mouse Chemicon, 
Temecula, CA, 
USA 
MAB3502 ACE denaturated from human 
kidney 
1:100 Balyasnikova IV, et al. Tissue 
Antigens 2003; 61: 49-62. 
ACE-2 polyclonal goat R&D Systems, 
Minneapolis, 
MN, USA 
AF933 NS0-derived rhACE-2 
ectodomain 
1:100 Pohl M, et al. J Biol Chem 2010; 
285: 41935-41946. 
ANP polyclonal rabbit Millipore, 
Billerica, MA, 
USA 
AB5490 Rat  ANP conjugated to BSA 1:200 Kawaguchi S, et al. J Histochem 
Cytochem 1989; 37: 1739-1742. 
CTGF polyclonal rabbit Abcam, 
Cambridge, 
UK 
Ab6992 Recombinant fragment 
corresponding to amino acid 
223-348 of mouse CTGF 
1:200 Samarakoon R, et al. Cell Signal 
2013; 25: 2198-2209. 
Nitrotyrosine polyclonal rabbit Upstate, Lake 
Placid, NY, 
USA 
06-284 Nitrated KLH 1:100 Jones MK, et al. Am J Physiol 
Gastrointest Liver Physiol 2011; 
301: G537-G546. 
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